Effect of intermediate- and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD 4 counts

Haemophilia

Volumn 3, Issue 4, 1997, Pages 265-269

  Deitcher, S R ^a   Tuller, J ^a   Dugdale, M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

CD4; Factor VIII; Haemophilia; HIV; Immune function

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; CD4 ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

EID: 0030721568     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00120.x     Document Type: Article

References (20)

1. Morfini M, Rafanelli D, Filimberti E, et al. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thromb Res 1989; 56: 169-78.
2. Lederman MM, Ratnoff OD, Scillian JJ, Jones PK, Schacter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med 1983; 308: 79-83.
3. Menitove JE, Aster RH, Casper JT, et al. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates. N Engl J Med 1983; 308: 83-6.
4. Gomperts ED, de Biasi R, De Vreker R. The impact of clotting factor concentrates on the immune system in individuals with hemophilia. Transfus Med Rev 1992; 6: 44-54.
5. Lederman MM, Saunders C, Toosi Z, Lemon N, Everson B, Ratnoff OD. Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 1986; 107: 471-8.
6. Hay CRM, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL-2 receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990; 75: 278-81.
7. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: A possible cause of immunosuppression in hemophiliacs. Br J Haematol 1989; 71: 387-91.
8. Eibl MM, Ahmad R, Wolf VM, Linnau Y, Götz E, Mannhalter JW. A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions. Blood 1987; 69: 1153-60.
9. Pasi KJ, Hill FGH. In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity. Br J Haematol 1990; 76: 88-93.
10. Seremetis SV, Aledort LM, Bergman GE, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet 1993; 342: 700-3.
11. de Biasi R, Rocino A, Miraglia E, Mastrulle L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-22.
12. Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW. Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341: 1373-4.
13. Goldsmith JM, Deutsche J, Tang M, Green D. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates. Thromb Haemost 1991; 66: 415-9.
14. Evans JA, Pasi KJ, Hill FGH. Evidence for the aetiological role of blood-borne virus infections in causing reduced lectin-induced T-cell proliferation in haemophilic boys. Br J Haematol 1995; 91: 197-202.
15. Goedert JJ, Cohen A R, Kessler CM, et al. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 1994; 344: 791-2.
16. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D, the Kogenate Study Group. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. Blood 1994; 83: 1958-62.
17. Mannucci PM, Gringeri A, de Biasi R, et al. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a highpurity or an intermediate-purity factor VIII (FVIII). Thromb Haemost 1992; 67: 310-13.
18. Brettler DB, Levine PH. Factor concentrates for treatment of hemophilia: which one to choose? Blood 1989; 73: 2067-73.
19. Gomperts E, Addiego J, Gill J. What is the impact of monoclonal Ab purified, plasma derived FVIII on immune function in hemophilia A patients? Blood 1989; 75 (Suppl. 1): 39a (abstract).
20. Gjerset GF, Pike MC, Mosley JW, et al. Effect of low- and intermediate- purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Blood 1994; 84: 1666-71.